Download Unicorn Signals App

Powered By EquityPandit
 Signals, Powered By  EquityPandit

Laurus Labs Shares Extend Gains as USFDA Approves HIV Drug

After the inspection, the US regulator issued a Form 483 with five observations.

Shares of Laurus Labs closed more than 1% on May 2, extending gains from another session after the US health regulator approved its HIV drug. The stock had risen more than 6% in the previous two sessions.

The pharmaceutical and biotech company told exchanges it had received preliminary approval from the USFDA for the world’s first orally dispersible film (ODF) for the paediatric ARV (antiretroviral) treatment Dolutegravir.

This would provide significant benefits regarding adherence to ARV drug therapy in paediatric HIV treatment.

Laurus Labs is also the first company to receive generic approval for the abacavir/dolutegravir/lamivudine fixed-dose combination for the second-line treatment of adult HIV patients.

Founder and CEO Satyanarayana Chava said, “This option will facilitate strict compliance and adherence to HIV treatment and benefit caregivers.”

The stock closed 1.3% higher at Rs 311.60 on the National Stock Exchange, with 4.55 million shares traded, up from a gain of more than 5% in the previous session.

Get Daily Prediction & Stocks Tips On Your Mobile